September 6 - 9, 2019
Westin Copley Place
Abstract submission deadline: Sunday, June 23
Advance registration deadline: Friday, July 26
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
AACR has designated this live activity for a maximum of 16.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Monday, October 21, 2019. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the on this webpage and via email. Your CME certificate will be sent to you via email after the completion of the activity.
According to the U.S. National Cancer Institute, pancreatic cancer will account for approximately 44,330 deaths in 2018. Pancreatic cancer will account for just 3.2% of all new cancer cases but will account for 7.3% of all cancer deaths. Despite advances in recent years, the 5-year survival rate is still just 8.2% - making pancreatic cancer one of the hardest to treat cancers.
Early detection and diagnosis are a primary area of concern in pancreatic cancer research. There are often no noticeable early symptoms and when symptoms do present in patients they are often misdiagnosed. Further complicating diagnosis, the pancreas is hidden behind other organs such as the stomach, small intestine, liver, gallbladder, spleen, and bile ducts. With sessions dedicated to genetic testing, imaging, and diagnostics, advances in these areas have the potential to increase the dismal survival rates for this disease.
Practicing oncologists and clinical investigators focused on pancreatic cancer will be drawn to the program to hear about applications of basic and translational research to patient care in the areas of local disease, diagnostics, imaging, immunotherapy, local disease management, and clinical trials.
After participating in this CME activity, physicians should be able to:
1. Evaluate the challenges and benefits of genetic testing in pancreatic cancer
2. Assess the efficacy of on recent advances made in modeling pancreatic cancer versus traditional model systems
3. Evaluate the promise of international and domestic clinical trial initiatives and the potential impact on patient care.
4. Explain the role of blood-based early detection in early diagnosis and the potential advantages of traditional diagnostic methods
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
This activity is supported by Professional Educational Grants and will be disclosed at the activity.
Please contact the Office of CME at (215) 440-9300 or firstname.lastname@example.org.